Blog

complex messy management, organization and innovation, chaotic decision tree, complicated business process

The process from pitching an idea ("Board") to its widespread use by clinicians and patients ("Ward") in HealthTech and MedTech is a multi-stage Health Technology Pathway focused on demonstrating value, ensuring safety, and securing buy-in. It is typically non-linear and requires constant engagement with diverse stakeholders.Here is an overview of the key phases:1. Idea Creation and Value Proposition (The Pitch) 💡 This initial phase establishes the foundation for the technology.Identify the Unmet Need: The process begins with identifying a clear problem or gap in clinical care that the proposed technology (device or digital solution) can solve. This must be a patient-centric need. Concept &amp; Development: The technology is designed with the end-user (clinicians and patients) in mind to ensure an intuitive and seamless experience that doesn't disrupt workflow. Value Proposition: A clear statement is developed to explain the benefits to the healthcare system, clinicians, and patients. This typically includes improvements in patient outcomes, cost-effectiveness, and/or operational efficiency. Early Engagement: Innovators engage early with key stakeholders, including regulators, commissioners, and patient groups, to align the technology's design and evidence requirements with the needs of the healthcare system.&nbsp;2. Regulatory Approval and Evidence Generation (The Validation) ✅ This is the critical phase where the technology is tested and formally approved for use.Clinical Trials/Testing: Rigorous studies are conducted to generate clinical evidence demonstrating the safety and effectiveness of the solution. This is essential for regulatory and adoption decisions. Regulatory Approval: The technology must meet stringent regulatory standards (e.g., FDA in the US, MHRA in the UK, MDR/IVDR in the EU) to be classified and marketed as a medical device or digital health solution. This often involves a risk-based approach, with higher-risk devices requiring more rigorous review. Health Technology Assessment (HTA): Independent bodies (like NICE in the UK) assess the clinical and cost-effectiveness of the technology compared to existing standard care. A positive HTA recommendation is often a prerequisite for national funding and commissioning. Post-Market Surveillance Planning: A plan is established for ongoing monitoring of the device's safety and performance once it's in use. 3. Funding, Commissioning, and Implementation (The Adoption) 🏥 Once the technology is proven safe and effective, the focus shifts to securing funding and integrating it into clinical practice.Funding and Procurement: The technology must secure a clear funding or reimbursement pathway. This involves navigating complex procurement routes and demonstrating the long-term value for money to health system commissioners. Commissioning and Local Planning: Healthcare organizations (e.g., Integrated Care Systems) decide to purchase and integrate the technology. This involves thorough mapping of existing clinical workflows to identify necessary process changes. Implementation &amp; Pilot Programs: A phased rollout is typically recommended, starting with pilot programs in specific departments or hospitals. This allows for real-world testing, gathering user feedback, and refining the implementation plan before a full-scale launch. Clinical Champion Buy-in: Identifying and empowering clinical champions—doctors, nurses, or other clinicians who are enthusiastic about the technology—is crucial. They drive local change, train peers, and provide essential feedback. 4. Clinician and Patient Adoption (The Ward) 🤝 The final stage ensures the technology is routinely and effectively used by its target users.Training and Support: Comprehensive, tailored training is provided to all end-users (clinicians, administrative staff, and patients). Ongoing, easily accessible support is vital to address issues as they arise. User-Centric Design: Technology adoption is significantly improved if the solution is intuitive and demonstrably saves the user time or significantly enhances patient care, rather than just adding to their workload. Continuous Feedback Loop: A mechanism for collecting and acting on feedback from frontline clinicians and patients must be established. This allows for iterative improvements to the product and the local implementation process. Measuring Outcomes: Organizations continuously monitor key performance indicators (KPIs) to ensure the technology delivers the promised benefits (e.g., reduced waiting lists, improved patient safety, better treatment outcomes). Cultural Change: Successful adoption requires overcoming system inertia and building a culture where innovation is valued and embedded into routine practice across the organization—the true "Board to Ward"culture.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Board to the Ward : Multi Stage  HealthTech and MedTech Pathway

November 2025 Calendar On Blue Background

Major European MedTech Developments (Week of Nov 10 - Nov 14, 2025) &nbsp;&nbsp; 1. Key Regulatory Milestone: CE Mark for Surgical Robotics &nbsp;&nbsp; The most significant development is a major market access approval: &nbsp;&nbsp; Zydus Lifesciences' 'Andy' Robotic Surgical System received the CE Mark approval.Implication: This approval validates its compliance with European safety standards and opens up market opportunities in the European Union for the system, which combines navigation technology with robotic assistance for orthopaedic surgeries (knee and hip). This reflects the growing focus on advanced surgical robotics in Europe. &nbsp;&nbsp; 2. Industry Spotlight: MedTech World Malta 2025 &nbsp;&nbsp; The MedTech world's attention has been on the major conference held this week: &nbsp;&nbsp; Event: MedTech World Malta 2025 took place, gathering over 2,000 global industry leaders, investors, and innovators.Government Focus: The Prime Minister of Malta highlighted a national ambition for Malta to become a leading European hub for MedTech, Life Sciences, and Digital Health, emphasising public-private partnerships, AI-driven healthcare projects, and investor interest.Activity:&nbsp; &nbsp;&nbsp; The event featured the MedTech World StartUp Pitch and workshops, indicating a strong focus on connecting emerging innovation with investment. &nbsp;&nbsp; 3. Regulatory Discussion: Navigating the EU AI Act &nbsp;&nbsp; Regulatory compliance for digital health remains a major topic: &nbsp;&nbsp; Concern: Experts at the European Digital Technology and Software conference expressed concerns that the recently enacted EU Artificial Intelligence (AI) Act poses a significant burden on new AI-enabled MedTech products.Industry Hope:&nbsp; &nbsp;&nbsp; There is an expectation that the European Commission's upcoming Digital Omnibus may provide some relief or clarity, potentially leading to delays in the strict implementation deadlines for AI-enabled healthcare products to allow manufacturers to catch up. &nbsp;&nbsp; 4. Investment and Funding &nbsp;&nbsp; While not a new deal this week, the investment climate is still dominated by a significant October venture loan: &nbsp;&nbsp; EIB Backing: The European Investment Bank (EIB) recently provided a €20 Million venture loan to German MedTech company PRECISIS GmbH.Focus: This funding is to support the further clinical development and international expansion of their EASEE® neuro stimulation therapy for drug-resistant epilepsy, which has been CE-certified since 2022 and is already in use across six European countries. &nbsp;&nbsp; In summary, the European MedTech sector this week saw a significant market entry for a new surgical robot, a major industry conference focusing on Malta as a future hub, and ongoing high-level discussions around the impact and implementation of the new AI Act on digital health products. &nbsp;&nbsp; &gt;&gt;&gt; &nbsp;&nbsp; Digital Health/HealthTech is currently driving much of the innovation in European healthcare.Building on the developments from this week, here are the major highlights specifically within the European HealthTech sector: &nbsp;&nbsp; Major European HealthTech Developments (Week of Nov 10 - Nov 14, 2025) &nbsp;&nbsp; The key themes this week are the European Union's regulatory simplification push and a strong, specialised investment focus on AI and chronic care. &nbsp;&nbsp; 1. EU Regulatory Movement: Digital Simplification Package &nbsp;&nbsp; The biggest news is the anticipated release of the European Commission's "Digital Package on Simplification," expected on November 19th. Focus: Leaked proposals indicate a major attempt to simplify and harmonize several existing digital laws that impact HealthTech, including GDPR, ePrivacy, and the AI Act. HealthTech Impact: &nbsp;&nbsp; AI Act Easing: There is ongoing debate and pressure (from both US and European tech companies) to delay the application of certain compliance deadlines for the High-Risk AI Systems classification. The industry hopes this delay will provide more time for digital health companies to meet the stringent requirements without stifling innovation. &nbsp;&nbsp; Data Reporting: Proposals suggest a lighter reporting regime for personal data breaches, allowing for a higher threshold for mandatory reporting and increasing the reporting window to 96 hours, which would ease the burden on HealthTech providers. &nbsp;&nbsp; Cookie Consent: Long-term plans advocate for moving away from repetitive cookie banners to universal, settings-based mechanisms for user preferences, which would streamline the patient experience on digital health platforms. &nbsp;&nbsp; 2. Targeted Investment &amp; Funding &nbsp;&nbsp; European investors are moving capital into specialised, scalable digital care models: &nbsp;&nbsp; Elder-Care Funding: Spanish HealthTech startup Qida secured a massive €37 Million funding round. This is noted as the largest investment ever in the elder-care sector in Spain, signalling a significant, growing investor appetite for tech-enabled home and long-term care models across the continent. &nbsp;&nbsp; Chronic Care Focus: The investment landscape continues to prioritise proven business models, with a recent focus on digital clinics for chronic conditions (such as obesity and epilepsy), which demonstrate clear patient value and reimbursement pathways. &nbsp;&nbsp; 3. AI in Practice and Policy &nbsp;&nbsp; AI is rapidly moving into real-world clinical application: &nbsp;&nbsp; Ambient AI for Clinicians: The launch of tools like Keikku 2.0 (a digital stethoscope with integrated AI Scribe) highlights the immediate demand for AI that automates documentation and assists diagnostics at the point of care, freeing up physician time. &nbsp;&nbsp; WHO/Europe AI Summit: Looking ahead, WHO/Europe and the Government of Malta are co-hosting a high-level meeting on November 19th titled "AI for Health and Care in Europe," aiming to launch a new regional report and explore practical, country-level solutions for ethical and responsible AI implementation in national health systems. &nbsp;&nbsp; EU HTA Regulation (Future Impact): The upcoming implementation of the new Health Technology Assessment (HTA) Regulation in 2025 is a long-term development that will significantly impact HealthTech. The regulation's goal is to unify clinical assessments across the EU, which will ultimately streamline how digital therapeutics and AI-driven diagnostics achieve reimbursement and market access in member states.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech and MedTech: 14th November 2025

The Mergers and Acquisitions (M&amp;A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions.&nbsp; &nbsp;&nbsp; This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinations.&nbsp; &nbsp;&nbsp; The single most potent catalyst driving deal value across both sectors is the urgent necessity to acquire advanced Artificial Intelligence (AI) and Generative AI (GenAI) capabilities, crucial for driving operational efficiency, streamlining workflows, and mitigating persistent margin compression. &nbsp;&nbsp; The market dynamic is shifting from a focus purely on innovation to one demanding demonstrable return on investment (ROI) derived from technological integration. Private Equity (PE) involvement remains high, supported by robust dry powder reserves, with sponsors focusing on both platform expansion and realising delayed exits into a receptive corporate buyer market."MedTech M&amp;A in 2026 will be characterised by aggressive moves to secure high-growth niches, integrate next-generation technology, and strategically manage portfolio risk, particularly in response to the GLP-1 drug phenome.""HealthTech M&amp;A in 2026 is fundamentally an infrastructure play, where AI and GenAI capabilities are acquired to automate and optimise the administrative and clinical workflows that account for a disproportionate amount of healthcare costs."Source: <a data-mce-href="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" href="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" title="https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/healthtech-and-medtech-mergers-and-acquisitions-predictions-for-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

The 2026 HealthTech and MedTech Deal Thesis

The high street wellness phenomenon represents a fundamental structural transformation of England’s town and city centres, shifting the core economic function from cyclical, transactional retail toward resilient, service-based, and experience-led health and wellbeing offerings. This transition is not merely cosmetic; it is driven by powerful macroeconomic forces, notably the structural resilience of the self-pay health consumer and targeted government intervention aimed at high street revitalisation. &nbsp;&nbsp; This analysis confirms the viability of High Street Wellness as an investment theme. High covenant, service-led operators, spanning clinical services, premium fitness and specialised beauty, are actively displacing traditional retail. This trend supports premium rental yields and robust asset valuation, particularly in prime London locations, which are seeing rents for specialised F&amp;B and wellness venues achieve £100–£150 per square foot annually. &nbsp;&nbsp; However, the market performance is highly stratified. Success directly correlates with local economic resilience, specifically high disposable income and favourable demographic profiles, particularly in Gen Z-led cities that prioritise experiential spending. The primary risk lies in generalised deployment across vulnerable, retail-dependent towns. Strategic capital must be directed toward integrated, technologically advanced service models within mixed use developments, leveraging the crucial alignment between commercial viability and public health policy, as outlined in the ‘Healthy High Streets’ mandate.High Street Wellness is defined by the physical manifestation of convergence across several sectors: preventative health, specialized beauty, bespoke fitness and supplementary secondary care services situated within traditional town centres. This evolution signifies a deep, structural transition within the commercial property landscape, fundamentally moving beyond transactional commerce to personalised, service based and experience focused consumer interactions. This model emphasizes customer longevity and high engagement over fleeting retail purchases. &nbsp;This shift holds critical implications for town planning and public policy. Local authorities and public health experts now recognise that the high street environment is highly influential in shaping overall health outcomes, acting as a crucial location where communities work, live, meet and consume. The recognition of high streets as social and environmental determinants of health has prompted policies explicitly focused on revitalising these areas. &nbsp;&nbsp; A key requirement for this revitalisation is the mixed use imperative. Policy actively promotes the development of mixed-use streets that combine commercial, residential, cultural, leisure, and service industries. This multi-functional approach is supported by evidence demonstrating that it encourages essential health determinants, including footfall, active travel (walking and cycling) and social interaction, which helps to build social capital and reduce isolation.Local decision-makers, including public health professionals and town managers, are officially advised to promote and support such mixed-use developments to enhance community well-being.The High Street Wellness movement in England is not a cyclical retail fad but a permanent, structural convergence of the retail and healthcare asset classes, driven by fundamental shifts in consumer values and healthcare provision. The demonstrable growth of the self-pay market (+38% self-pay admissions since 2019) validates the consumer's essentialisation of wellness expenditure. &nbsp;By strategically allocating capital based on economic resilience (local income), demographic drivers (Gen Z experience demand), and strict adherence to the scalable operational requirements (integration, consistency), investors can secure assets that offer superior covenant strength and attractive yields. The successful High Street Wellness asset anchors the new service-led urban economy and aligns commercial viability with the sustainable goals of the Wellbeing Economy.Source: <a data-mce-href="https://www.healthcare.digital/single-post/high-street-wellness-and-private-health-consumers-emerging-new-trend-for-2026" href="https://www.healthcare.digital/single-post/high-street-wellness-and-private-health-consumers-emerging-new-trend-for-2026" title="https://www.healthcare.digital/single-post/high-street-wellness-and-private-health-consumers-emerging-new-trend-for-2026" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/high-street-wellness-and-private-health-consumers-emerging-new-trend-for-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

High Street Wellness: Emerging New Trend for 2026

Nelson Advisors has been invited to join the 'Startups and Corporates: How to Build Meaningful Partnerships in MedTech' panel at MedTech Europe 2025. Nelson Advisors Partner Lloyd Price will join fellow panellists including: &nbsp;&nbsp; NICOLE BLACK, Program Director, MedTech Innovator &nbsp;&nbsp; KHURRAM MIR, Managing Director, UCI Health &nbsp;&nbsp; DAVID UFFER, Managing Director, Medtech, Trinity Life Sciences &nbsp;&nbsp; SANJAY SHRIVASTAVA, PH.D, CEO and Founder, Innova Vascular, Inc &nbsp;&nbsp; OSAMA ALSALEH, Head of Partnerships, Health, Plug and PlayThe focus of the panel will be a discussion on creating successful collaborations between startups and corporates, focusing on alignment, trust, and shared value to accelerate MedTech innovation.MedTech Malta 2025 &nbsp;&nbsp; The MedTech Malta 2025 event is a three-day summit scheduled to take place from November 12-14, 2025, at the Mediterranean Conference Centre in Valletta, Malta. 🇲🇹 &nbsp;&nbsp; What to Expect at MedTech Malta 2025 &nbsp;&nbsp; The conference is a convergence point for a global audience, including investors, entrepreneurs and healthcare leaders. It aims to foster collaboration and showcase the latest advancements in medical technology. The agenda includes: &nbsp;&nbsp; Panel Discussions &amp; Keynotes: featuring experts from various fields within the MedTech ecosystem. Startup Pitch Competitions: offering a platform for emerging companies to showcase their innovations. Exhibitions: with a focus on cutting-edge technologies. Networking Opportunities: including exclusive forums for CEOs and investors. Cultural Activities &amp; Awards Gala: the event is set against the backdrop of Malta's historic capital, with a cultural tour and the prestigious MedTech World Awards Ceremony. The conference is a CPD-accredited event, providing healthcare professionals with an opportunity for professional development. &nbsp;&nbsp; <a data-mce-href="https://med-tech.world/malta/" href="https://med-tech.world/malta/" title="https://med-tech.world/malta/" target="_blank" rel="noopener">https://med-tech.world/malta/</a>

Nelson Advisors at MedTech Europe 2025

The 4 A's of healthcare AI—Augment, Adopt, Align, and Adapt, represent a framework focused on ensuring that the development and deployment of Artificial Intelligence in healthcare is effective, ethical, and centered on human needs. This framework, particularly promoted by organisations focusing on behavioural science in AI, can be applied to many sectors, including healthcare.🧠 The 4 A's of Healthcare AI Here is a breakdown of what each 'A' typically addresses in the context of AI and human behaviour, especially in a sensitive sector like healthcare:1. Augment: This principle focuses on how AI can enhance and extend human capabilities rather than replacing them. In healthcare, it emphasises the concept of "Augmented Intelligence," meaning AI tools should support clinicians by improving diagnostic accuracy, personalising treatment, reducing administrative burdens, and accelerating research, while still keeping human oversight, empathy and judgment central to care.2. Adopt: This addresses the practical challenge of getting individuals and organizations to use AI effectively. It requires understanding the human factors, what motivates healthcare professionals and institutions to use or resist AI and designing systems and workflows that encourage meaningful uptake and deep integration of the technology into clinical practice, moving beyond simple, shallow use.3. Align: This critical component ensures that AI systems are designed to fit human psychology, behavior, and values. In healthcare, this means developing AI that is:Trustworthy (reliable, safe, and transparent). Ethical (free from bias and protecting patient privacy). Consistent with the goal of patient-centered care. Alignment involves embedding explainability and interpretability into the AI's core architecture. 4. Adapt: This looks at the systemic and societal changes necessary to accommodate the widespread use of AI. For healthcare, this involves:Updating regulations and governance structures. Evolving professional roles and training (e.g., ensuring clinicians maintain core skills while learning to work effectively with AI). Preparing the entire healthcare system and public to manage the new ethical and operational challenges AI presents. This framework shifts the focus from purely technical capabilities to the holistic integration of AI within human systems, which is vital for high-stakes environments like medicine.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Board to the Ward : Multi Stage HealthTech and MedTech P...

This Week in European HealthTech and MedTech: 14th Novemb...

The 2026 HealthTech and MedTech Deal Thesis

High Street Wellness: Emerging New Trend for 2026

Nelson Advisors at MedTech Europe 2025

The 4 A's of Healthcare AI